AADI (Aadi Bioscience, Inc.) Enterprise Value-to-Revenue Coefficient

Aadi Bioscience relies on a deep scientific foundation and targeted mTOR inhibitors. The company generates revenue from the sale of innovative oncology drugs, although slow sales growth and R&D expenses limit profitability. The EV/Sales trend on the GURU.Markets base chart visualizes these fundamental factors, and this metric settled at .
Financial and market metric breakdowns for Aadi Bio (AADI)

To isolate fundamental stability from market noise, a metric is used that compares the total enterprise value of the business with annual sales volume minus debt obligations. By analyzing the EV/Sales multiple history, an investor can see the real asset valuation of Aadi Bioscience (AADI), whose strategy of mastering narrow niches in targeted therapy for rare tumors creates a protected foundation for the company's capitalization.